Expression profile of @entity5 genes in transitional cell XXXX .

@entity72984 @entity8214 @entity5 @entity150 @entity6472 @entity16051 @entity5840
OBJECTIVES: To explore the expression profile of multiple @entity5 ( @entity5 ) genes in transitional cell @entity150 ( @entity8214 ), and investigate its possible correlation with clinicopathologic characteristics. METHODS: The mRNA expression of 6 @entity5 genes was detected using reverse transcription polymerase chain reaction (RT-PCR) for 102 @entity8214 samples (59 Ta-T1, 43 T2-T4, 44 G1, 32 G2, and 26 G3 samples) as well as the matching adjacent normal bladder mucosa for each sample. The @entity5840 protein expression was also determined by immunoblotting. Immunohistochemistry was performed in selected samples to confirm the @entity5840 protein expression. RESULTS: The mRNA expression of all 6 @entity5 genes was detected with relatively high frequencies in @entity8214 tissues. The percent of samples positive for each gene in the @entity8214 samples are: @entity5840 , 58.8%; @entity6472 , 56.9%; @entity72984 , 52.9%; MAGE-A12, 51%; @entity72984 , 49%; and @entity16051 , 45.1%. Furthermore, @entity5840 protein expression was positive in 52.9% of @entity8214 tissues by immunoblotting. Immunohistochemistry showed an exclusively cytoplasmic staining pattern of @entity5840 protein. Neither @entity5 gene mRNA expression nor @entity5840 protein expression was found in the adjacent normal tissue. There was no significant correlation between @entity5 gene expression and clinicopathologic characteristics (P > 0.05). CONCLUSIONS: All six @entity5 genes are highly expressed in @entity8214 , and may serve as therapeutic targets of specific immunotherapy for @entity8214 , especially in multi-antigen vaccine preparations.
